期刊文献+

萘哌地尔衍生物BWYJ抗前列腺增生的作用 被引量:2

Effect of naftopidil' ramification-BWYJ on benign prostatic hyperplasia in mice and rats
下载PDF
导出
摘要 目的观察萘哌地尔衍生物BWYJ对前列腺增生模型的作用。方法采用激素法建立去势大鼠和未去势小鼠前列腺增生模型,通过小鼠前列腺湿重,计算前列腺指数。光镜及透射电镜下,分别观察小鼠前列腺组织形态学及超微结构变化;TUNEL法检测BWYJ对大鼠前列腺细胞凋亡的影响。结果BWYJ5、10、20mg·kg-1组均可降低BPH小鼠前列腺湿重指数(P<0.05),光镜及电镜结果表明,BWYJ5、10、20mg·kg-1组均可抑制小鼠组织结构增生性变化,且BWYJ10、20mg·kg-1组使腺腔直径、腺体表面积变小(P<0.05)。TUNEL检测发现,大鼠前列腺凋亡细胞检出率较低,与模型组比较,BWYJ各剂量组差异无统计学意义(P>0.05)。结论BWYJ具有抗小鼠及大鼠良性前列腺增生作用。 AIM:To observe the effect of naftopidilderivant BWYJ on benign prostatic hyperplasia (BPH) induced by testosterone propionate in castrated rats and uncastrated mice. METHODS: Castrated rats and uncastrated mice were injected subcutaneously testosterone propionate to induce BPH. The effect of BWYJ on mice with BPH was obtained by the prostatic wet weight and wet weight index. As well morphological changes of prostate were observed through light microscope and electron microscope, and were semi-quantified by image analysis system. The apoptotsis of prostatic cells in rat was detected by TUNEL assay. RESULTS:BWYJ decreased the prostate wet weight index ( P 〈 0.05). BWYJ inhibited histomorphological changes of BPH induced by testosterone propionate in uncastrated mice. Few apoptosis cell was detected by TUNEL assay in BWYJ-treated groups compared with model group ( P 〉 0.05 ). CONCLUSION: BWYJ inhibits BPH induced by testosterone propionate in KM mice and SD rat.
出处 《中国临床药理学与治疗学》 CAS CSCD 2006年第8期873-877,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 国家自然科学基金项目(№30060087) 贵州省科技基金重点项目(计[2002(3014)])
关键词 萘哌地尔衍生物 BWYJ 前列腺增生 组织形态学 电镜 细胞凋亡 naftopidil' ramification BWYJ benign prostatic hyperplasia histopathology electron microscope apoptosis
  • 相关文献

参考文献12

二级参考文献50

  • 1李宁忱,张晓春,王晓峰,吴宏飞,那彦群,郭应禄.新型α_1-肾上腺素能受体阻滞剂萘哌地尔治疗良性前列腺增生的临床研究[J].中华泌尿外科杂志,2004,25(9):637-640. 被引量:21
  • 2王会玖,黄燮南,蒋青松,吴芹,孙安盛,石京山.萘哌地尔衍生物BWYJ扩张血管效应及其机理研究[J].中国临床药理学与治疗学,2004,9(12):1393-1397. 被引量:11
  • 3[1]Peter G,Niebch G,Locher M,et al.Pharmacokinetic fate of the novel antihypertensive drug naftopidil[J].Arzneimittelforschun g,1991,41(9)∶924-93 1.
  • 4[2]Niebch G,Locher M,Borbe HO.Metabolic fate of the novel antihypert ensive drug naftopidil[J].Arzneimittelforschung,1991,41(10)∶1027-1032.
  • 5[3]Borbe HO,Peter G.Radioreceptor assay for the determination of alp ha1-adr enoceptor-binding material in rat plasma following single oral administration o f naftopidil[J].Arzneimittelforschung,1990,40(3)∶253-256.
  • 6[4]Niebch G, Borbe HO,Besenfelder E.High-performance liquid chromat ography of naftopidil,a novel antihypertensive drug, and two metabolites in human plasm a[J].J Chromatogr,1990,534∶247-252.
  • 7[5]Terakado T,Oki E,Iida M,et al.Metabolism of naftopidil (KT-6 11) in healthy volunteers[J].J Clin Ther Med,1992,8(Suppl 3)∶S3-S9.
  • 8[6]NN.Naftopidil:Investigational Drug Brochure[R].ASTA Medica AG,1 992.
  • 9[7]Takagi N,Ishii M,Takeda K,et al.Pharmacokinetics of naftopidi l (KT-6 11) in hypertensive patients with renal impairment or normal renal function[J] .J Clin Ther Med,1992,8(Suppl 3)∶S109-S122.
  • 10[8]Farthing MJ,Alstead EM,Abrams SM,et al.Pharmacokinetics of na ftopidil ,a novel anti-hypertensive drug,in patients with hepatic dysfunction[J].Pos tgrad Med J,1994,70(823)∶363-366.

共引文献49

同被引文献12

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部